Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03534180 · ClinicalTrials.gov registry record · Phase 2
Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma
A Phase 2 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT03534180 is a Phase 2 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 12 participants.
The verdict
NCT03534180, a Phase 2 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This phase II trial studies the side effects and best dose of venetoclax and romidepsin to see how well it works in treating patients with mature T-cell lymphoma that has come back (recurrent) or does not respond to treatment (refractory). Venetoclax and romidepsin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG Venetoclax
- OTHER Laboratory Biomarker Analysis
- DRUG Romidepsin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-08-21 |
| Est. Completion | 2023-07-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03534180
The ClinicalTrials.gov registry entry for NCT03534180 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Venetoclax is the first listed.
NCT03534180 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03534180 about?
NCT03534180 is a clinical study titled "Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma". This phase II trial studies the side effects and best dose of venetoclax and romidepsin to see how well it works in treating patients with mature T-cell lymphoma that has come back (recurrent) or does not respond to treatment (refractory). Venetoclax and romidepsin may stop the growth of cancer cell...
What is the current status of trial NCT03534180?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2018-08-21. Estimated completion is 2023-07-26.
What interventions are being tested in trial NCT03534180?
The interventions under investigation include: Venetoclax (DRUG), Laboratory Biomarker Analysis (OTHER), Romidepsin (DRUG).
Who is sponsoring clinical trial NCT03534180?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.